Monthly Archives: February 2020

Although inflammatory bowel disease (IBD) is heritable, the heritability is still largely unexplained despite substantial progress through GWAS and WGS. However, recent advances in epigenetics (gene environmental interactions), including DNA methylatio… Continue reading →

Chronic granulomatous disease (CGD) is a rare disorder caused by genetic mutations of the nicotinamide adenine dinucleotide phosphate oxidase complex (NADPH), occurring in approximately 1/200,000 individuals. These mutations decrease residual reactive … Continue reading →

Although therapeutics in Crohn’s disease (CD) have dramatically improved, current approaches targeting the immune system have limited success at a population level. Thus, there is a need for future therapeutics to target different pathways/cell types. … Continue reading →

To evaluate the effect of remission status on physical activity, and body composition in pediatric patients with inflammatory bowel disease (PIBD) and healthy peers. Continue reading →

C1ORF106, also named INAVA (Innate Immune Activator), was identified as a risk gene for the chronic inflammatory bowel diseases (IBD) by genome-wide association studies and targeted exome sequencing. INAVA is highly enriched in polarized simple epithel… Continue reading →

The subtype of inflammatory bowel disease (IBD) is often not known at index colonoscopy and examining for perianal disease (PAD) can assist in establishing the diagnosis. PAD is common in Crohn’s disease (CD) but can also be seen in patients with ulcer… Continue reading →

Patients with inflammatory bowel disease demonstrate selenium nutritional deficiencies and are at increased risk for colon cancer. Previously, we determined that global loss of the selenium-containing antioxidant protein, Selenoprotein P (SELENOP), exa… Continue reading →

Sweat based wearable sensors have shown a lot of promise in the recent years due to the ability of tracking the biomarkers in real-time. Among the various biomarkers present in sweat, cytokine concentrations have been shown in comparable range to the b… Continue reading →

While the direct cause of inflammatory bowel disease (IBD) is unknown, the gut microbiota is speculated to play a key role. The complexity of the microbiome has made it difficult to pinpoint whether bacterial species are specifically associated with IB… Continue reading →

Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis (UC). Safety and efficacy of tofacitinib were evaluated in 2 Phase 3 induction studies (OCTAVE Induction 1 & 2, NCT01465763 & NCT01458951), a 52-week (wk), Pha… Continue reading →